Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia

British Journal of Haematology

Volumn 138, Issue 1, 2007, Pages 77-81

  Curtis, Claire E ^a   Grand, Francis H ^a   Musto, Pellegrino ^b   Clark, Andrew ^c   Murphy, John ^c   Perla, Gianni ^d   Minervini, Maria M ^d   Stewart, Janet ^e   Reiter, Andreas ^f   Cross, Nicholas C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c MONKLANDS HOSPITAL   (United Kingdom)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic eosinophilic leukaemia; ETV6; Imatinib; PDGFRA; STRN

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CHRONIC EOSINOPHILIC LEUKEMIA; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG SENSITIVITY; DRUG WITHDRAWAL; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HUMAN; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CALMODULIN-BINDING PROTEINS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 4; HUMANS; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; ONCOGENE FUSION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ETS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 34250007662     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06628.x     Document Type: Article

References (12)

1. Bartoli, M., Monneron, A. Ladant, D. (1998) Interaction of calmodulin with striatin, a WD-repeat protein present in neuronal dendritic spines. Journal of Biological Chemistry, 273, 22248 22253.
2. Baxter, E.J., Hochhaus, A., Bolufer, P., Reiter, A., Fernandez, J.M., Senent, L., Cervera, J., Moscardo, F., Sanz, M.A. Cross, N.C.P. (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 11, 1391 1397.
3. Bohlander, S.K. (2005) ETV6: a versatile player in leukemogenesis. Seminars in Cancer Biology, 15, 162 174.
4. Cools, J., Bilhou-Nabera, C., Wlodarska, I., Cabrol, C., Talmant, P., Bernard, P., Hagemeijer, A. Marynen, P. (1999) Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13). Blood, 94, 1820 1824.
5. Cools, J., De Angelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., Cross, N.C., Tefferi, A., Malone, J., Alam, R., Schrier, S.L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S.E., Stone, R. Gilliland, D.G. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine, 348, 1201 1214.
6. Griffin, J.H., Leung, J., Bruner, R.J., Caligiuri, M.A. Briesewitz, R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 100, 7830 7835.
7. Lu, Q., Pallas, D.C., Surks, H.K., Baur, W.E., Mendelsohn, M.E. Karas, R.H. (2004) Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proceedings of the National Academy of Sciences of the United States of America, 101, 17126 17131.
8. Musto, P., Falcone, A., Sanpaolo, G., Bodenizza, C., Perla, G., Minervini, M.M., Cascavilla, N., Dell'Olio, M., La, S.A., Mantuano, S., Melillo, L., Nobile, M., Scalzulli, P.R., Bisceglia, M. Carella, A.M. (2004) Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leukemia & Lymphoma, 45, 1219 1222.
9. Reiter, A., Walz, C. Cross, N.C.P. (2007) Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Current Drug Targets, 8, 205 216.
10. Score, J., Curtis, C., Waghorn, K., Stalder, M., Jotterand, M., Grand, F.H. Cross, N.C.P. (2006) Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia, 20, 827 832.
11. Stover, E.H., Chen, J., Folens, C., Lee, B.H., Mentens, N., Marynen, P., Williams, I.R., Gilliland, D.G. Cools, J. (2006) Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proceedings of the National Academy of Science of the United States of America, 103, 8078 8083.
12. Walz, C., Curtis, C., Schnittger, S., Schultheis, B., Metzgeroth, G., Schoch, C., Lengfelder, E., Erben, P., Muller, M.C., Haferlach, T., Hochhaus, A., Hehlmann, R., Cross, N.C.P. Reiter, A. (2006) Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes, Chromosomes & Cancer, 45, 950 956.